New drug targets genetic weakness in bladder cancer
NCT ID NCT03047213
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This phase 2 trial tests a drug called sapanisertib in 17 people with advanced bladder cancer that has a specific genetic change (TSC1 or TSC2 mutation). The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if the drug can shrink tumors and how safe it is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Keck Medical Center of USC Pasadena
Pasadena, California, 91105, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Nebraska Medicine-Bellevue
Bellevue, Nebraska, 68123, United States
-
Nebraska Medicine-Village Pointe
Omaha, Nebraska, 68118, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut, 06510, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Kansas Clinical Research Center
Fairway, Kansas, 66205, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee, 37204, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
-
Yale University
New Haven, Connecticut, 06520, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sapanisertib (a drug that blocks a protein called mTOR to slow cancer growth)
What this could lead to
If it works, this could point toward a targeted treatment for bladder cancer patients with specific genetic mutations.
What could go wrong
This is a very small, early-phase trial with only 17 participants, so results may not apply to everyone. The drug may cause side effects and may not shrink tumors in most patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.